{
  "docId": "019de075-1718-756f-8ae4-37f1cf0d16ed",
  "docSlug": "2a95ead0d9ef429fb8fb8c2cc4a7d704",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 52 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 13,
  "pageCount": 52,
  "prevPage": 12,
  "nextPage": 14,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 40,
  "notes": "Kaplan-Meier survival curves showing primary (2020) and updated (2023) analysis results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-1718-756f-8ae4-37f1cf0d16ed/13",
  "deckHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed",
  "deckJsonHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed.json",
  "deckAnchorHref": "/decks/019de075-1718-756f-8ae4-37f1cf0d16ed#slide-13",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.08,
        "y": 0.25
      },
      "kind": "chart",
      "text": "ADAURA primary DFS analysis",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ddaa8425-7464-416a-8203-22c46ea3b8a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.5,
        "w": 0.4,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "chart",
      "text": "ADAURA updated DFS analysis",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f6fa3f78-a732-4564-876d-9e9bbef9a3c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.85,
        "x": 0.08,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "Adjuvant Tagrisso has demonstrated a highly statistically significant and clinically meaningful improvement in DFS in completely resected, EGFRm NSCLC vs placebo in both the primary (stage II-IIIA) and overall (IB-IIIA) populations, along with a tolerable safety profile",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca33c126-c9f1-4e87-a288-9e1eb52d0ec7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.9,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Data cut-off: January 17, 2020. Data cut-off: April 11, 2022. Wu et al. N Engl J Med 2020;383:1711-1723; Herbst et al. J Clin Oncol 2020;38(Suppl 18): abstract / oral LBA5; Herbst et al. J Clin Oncol 2023;41:1830-1840; Tsuboi et al. Ann Oncol 2022;33(Suppl 7): abstract / oral LBA4.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94f13124-dc78-4386-8fea-34b78b7d4528",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.7,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Adjuvant Tagrisso has significantly improved DFS",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8abf1be-a15d-4598-bdfc-14d476e7b074",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "evidence-matrix",
      "slug": null,
      "matchId": "cd43a8db-f08c-4ad4-aea4-f26c22d99a28",
      "evidence": "Comparison of primary and updated clinical trial data points",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 14,
      "from": 8,
      "beatId": "825356c1-11c2-4d2a-9dc4-e3ccfd780129",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The deck highlights the company's diverse portfolio and pipeline, emphasizing the potential for combinations",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 14,
      "from": 8,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "5bb0992b-1a81-4416-bc2d-f98f5d61437b",
      "evidence": "The deck highlights the company's diverse portfolio and pipeline, implying that innovation is crucial",
      "position": 0,
      "objective": "What if AstraZeneca doesn't innovate in oncology?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}